Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology therapies using its proprietary AP3 platform. The company’s lead programs are ACR-368 and ACR-2316, and it also develops drug-tailored OncoSignature tests intended to match patients to the right therapy. Acrivon has not yet generated product revenue and is still funding research, clinical development, manufacturing scale-up, and regulatory preparation. Its business model is centered on advancing drug candidates through trials, then seeking approvals and, if successful, commercializing directly or through partnerships.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueSmall-molecule oncology assets in human trials, including ACR-368 and ACR-2316.
OncoSignature tests designed to identify patients most likely to respond to Acrivon’s therapies.
The AP3 platform used to optimize compounds in intact cells and support pipeline generation.
Earlier-stage drug discovery and validation programs that may become future clinical assets.
cGMP process development, clinical supply manufacturing, and scale-up activities for candidates.
Customers
Acrivon does not currently sell approved medicines, so its near-term “customers” are primarily clinical trial sites, investigators, and contract research/manufacturing partners that support development. In the future, if its candidates are approved, the company would sell to oncology patients through hospitals, cancer centers, and specialty prescribers, potentially with reimbursement from payers. The OncoSignature test also implies a companion-diagnostic use case where clinicians and treatment centers would use the assay to guide patient selection. The company may also pursue collaboration partners or licensing counterparties that provide upfront fees, milestones, or R&D reimbursements before commercial launch.
CROs, trial sites, and manufacturing partners that execute studies and produce clinical supply for ACR-368, ACR-2316, and related programs.
Oncologists and cancer centers that would prescribe approved products if Acrivon reaches commercialization.
Insurers and health systems that would influence uptake by deciding coverage and reimbursement for approved therapies.
Biopharma partners that may provide upfront fees, milestones, or R&D funding in exchange for rights or access.
Clinicians and treatment centers that would use the OncoSignature test to identify likely responders.
Strategy
Acrivon’s strategy is to advance ACR-368 and ACR-2316 through clinical development while continuing to build a broader pipeline from its AP3 platform. The company is also investing in drug-tailored OncoSignature tests to improve patient selection and potentially strengthen the clinical and commercial profile of its therapies. A second priority is to mature manufacturing, regulatory, and commercial infrastructure so it can support approval and launch if a candidate succeeds. Management also highlights the option to use collaborations, licensing, or in-licenses/acquisitions to extend the pipeline and reduce dependence on any single asset.
Clinical proof-of-concept is the main value driver because the company has no approved products or revenue.
AP3-based discovery can create follow-on assets and reduce dependence on a single program.
If a candidate is approved, the company must be able to supply, market, and distribute product.
The company expects to need additional funding and may use collaborations to extend runway and reduce dilution.
Geography
Acrivon is a U.S.-based company and its reporting emphasizes operations and funding needs in the United States, where its clinical development, regulatory strategy, and public-company obligations are centered. The company states that it may seek regulatory approvals in the United States and other jurisdictions, which means future commercialization could become multi-region. Its current exposure is therefore driven more by U.S. clinical, regulatory, and capital-market conditions than by international sales. The reports also note geopolitical disruption risk, including the Russia-Ukraine war and Middle East conflict, which can affect trial execution, supply chains, and operating continuity.
Risks
Acrivon is a pre-revenue biotech with no approved products, so its core risk is that clinical candidates may fail, be delayed, or never reach commercialization. The company expects substantial losses for several years and may need additional capital, which creates dilution and financing risk if markets are unfavorable. Its operations also depend on trial execution, manufacturing capacity, regulatory review, and intellectual property protection, all of which are uncertain and can materially affect value. Broader industry risks include competition from other oncology platforms, changing regulatory standards, reimbursement hurdles, and geopolitical or public-health disruptions that can slow enrollment or supply.
- Clinical development failureImpact: CriticalLikelihood: High
The company’s value depends on ACR-368, ACR-2316, and future candidates proving safe and effective in trials.
Exposure: Lead oncology programs
- Financing and dilution riskImpact: HighLikelihood: High
Acrivon expects to burn cash for years and may need equity, debt, or collaboration funding before commercialization.
Exposure: Corporate funding
- Regulatory approval riskImpact: HighLikelihood: High
Even successful trials do not guarantee approval, and post-marketing studies or jurisdiction-specific requirements may add cost and delay.
Exposure: FDA and other regulators
- Manufacturing and supply riskImpact: HighLikelihood: Low
Clinical and future commercial supply depends on cGMP process development and third-party manufacturing capacity.
Exposure: Clinical supply and scale-up
- Geopolitical and trial disruption riskImpact: MediumLikelihood: Medium
Management explicitly cites public-health emergencies and geopolitical events as potential causes of trial and operational disruption.
Exposure: Global trial operations
- Intellectual property riskImpact: MediumLikelihood: Low
The company relies on patents, licenses, and know-how to protect its platform and candidates from competitors.
Exposure: AP3 platform and pipeline
Accounting
Judgemental itemsTrial costs, manufacturing, and preclinical work are expensed as incurred, so the timing of studies directly affects quarterly losses.
Impact: High quarter-to-quarter volatility in operating results
Personnel-related costs include equity compensation, which can materially affect R&D and G&A expense as headcount grows.
Impact: Reported losses and operating expense mix
The company references licensing arrangements and future milestone payments, which can create contingent or future cash obligations.
Impact: Future expense and cash outflow uncertainty
With no product revenue, investors must assess whether existing cash is sufficient to fund development through key milestones.
Impact: Liquidity and financing analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Theriva Biologics, Inc.
TOVX · Pharmaceutical Preparations
Genprex, Inc.
GNPX · Pharmaceutical Preparations
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
Last updated: 24/09/2026